Search

Your search keyword '"Salcedo, P. G."' showing total 14 results
Start Over Author "Salcedo, P. G."
14 results on '"Salcedo, P. G."'

1. Primary Cancer Sites and Clinical Features of Choroidal Metastasis in Mexican Patients

Author

Salcedo-Villanueva G, Medina-Andrade AA, Moreno-Paramo D, Golzarri MF, Moreno-Paramo E, Ortiz-Ramirez GY, Martinez-Aguilar U, De Dios-Cuadras U, Jimenez-Rodriguez M, Espinosa-Soto I, Mira-Lorenzo X, Guzman-Cerda J, Orozco-Moguel A, Becerra-Revollo C, Orozco-Gomez LP, and Fulda E

Subjects
choroidal neoplasms, eye neoplasms, neoplasm metastasis, ovarian neoplasms, testicular neoplasms, Ophthalmology, RE1-994
Abstract

Guillermo Salcedo-Villanueva,1 Abraham Alejandro Medina-Andrade,1 Daniel Moreno-Paramo,2 Maria Fernanda Golzarri,1 Edel Moreno-Paramo,1 Grecia Yael Ortiz-Ramirez,1 Ursula Martinez-Aguilar,3 Ulises De Dios-Cuadras,3 Martin Jimenez-Rodriguez,4 Itzel Espinosa-Soto,4 Ximena Mira-Lorenzo,5 Juvenal Guzman-Cerda,5 Andres Orozco-Moguel,6 Catalina Becerra-Revollo,1 Luis Porfirio Orozco-Gomez,7 Emiliano Fulda3 1Retina Department, Asociación Para Evitar la Ceguera en México, Hospital “Dr. Luis Sánchez Bulnes”, Mexico City, Mexico; 2Ophthalmology Department, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico; 3Retina Department, Instituto de Oftalmología Fundación Conde de Valenciana, Mexico City, Mexico; 4Retina Department, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico; 5Retina Department, Instituto Mexicano de Oftalmología, Santiago de Queretaro, Mexico; 6Facultad de Medicina, Universidad Nacional Autónoma de México; 7Retina Department, Centro Médico Nacional 20 de Noviembre, Mexico City, MexicoCorrespondence: Guillermo Salcedo-Villanueva RetinaDepartment, Asociación Para Evitar la Ceguera en México, Hospital “Dr Luis Sánchez Bulnes”, IAP, Vicente García Torres 46, Col. San Lucas, Coyoacan, Mexico City, CP 04030, MexicoTel +52 55 10841400, Ext 1172Email guillermo.salcedo@apec.com.mxPurpose: To describe the primary cancer sites and clinical features of choroidal metastasis in Mexican patients.Methods: This was a retrospective, observational, and multi-center study. Data were recollected from 6 ophthalmological hospitals in Mexico from patients with choroidal metastasis diagnosed from 2000 to 2018.Results: Seventy-eight patients were studied: 43 were female and 35 were male. Mean age at presentation was 57.6 years. Overall, primary cancer sites were: 1) breast: 27 cases (34.6%); 2) lung: 19 cases (24.3%); 3) unknown: 8 cases (10.2%); 4) gastrointestinal: 7 cases (8.9%); 5) renal: 5 cases (6.4%); 6) testicular: 3 cases (3.8%); 7) ovary: 3 Cases (3.8%); 8) prostate: 2 cases (2.5%); 9) thyroid: 2 cases (2.5%); 10) carcinoid: 1 case (1.2%); and 11) multiple myeloma: 1 case (1.2%). Divided by gender, for women, the main three sites were: breast, unknown, and ovary. For men, the main three sites were: lung, gastrointestinal, and testicular. Oldest cases were breast cancer (87 and 85 years); youngest cases were testicular (23 and 25 years). Solitary lesions were observed in 56 cases (71.7%); multiple lesions were observed in 22 cases (28.2%). Forty-two cases had a white or yellowish color, while 6 cases presented an orange color.Conclusion: Primary cancer sites and clinical features of choroidal metastasis in Mexican patients show important differences from other populations previously studied, mainly the presence of a higher proportion of gastrointestinal and renal cancer, as well as higher incidence of ovarian and testicular cancer. These types of cancer, although not as common as breast or lung, need to be taken into account when studying Mexican patients living abroad.Keywords: choroidal neoplasms, eye neoplasms, neoplasm metastasis, ovarian neoplasms, testicular neoplasms

Published
2021

2. A Proposed Method to Quantify Vitreous Hemorrhage by Ultrasound

Author

Salcedo-Villanueva G, Trujillo-Alvarez M, Becerra-Revollo C, Ibarra-Elizalde E, Mayorquín-Ruiz M, Velez-Montoya R, García-Aguirre G, Gonzalez-Salinas R, Morales-Cantón V, Quiroz-Mercado H, and Moragrega-Adame E

Subjects
diagnostic imaging, retina, ultrasonography, vitreous hemorrhage, vitreous humor, Ophthalmology, RE1-994
Abstract

Guillermo Salcedo-Villanueva,1 Manuel Trujillo-Alvarez,1 Catalina Becerra-Revollo,2 Estefanía Ibarra-Elizalde,2 Mariana Mayorquín-Ruiz,2 Raul Velez-Montoya,1 Gerardo García-Aguirre,1 Roberto Gonzalez-Salinas,3 Virgilio Morales-Cantón,1 Hugo Quiroz-Mercado,1 Eduardo Moragrega-Adame2 1Retina Department, Asociación Para Evitar La Ceguera En México, Mexico City, Mexico; 2Ocular Ultrasound Department, Asociación Para Evitar La Ceguera En México, Mexico City, Mexico; 3Research Department, Asociación Para Evitar La Ceguera En México, Mexico City, MexicoCorrespondence: Guillermo Salcedo-VillanuevaRetina Department, Asociación Para Evitar La Ceguera En México, Vicente García Torres #46. Col. San Lucas, Coyoacán, Mexico City 04030, MexicoEmail guillermo.salcedo@apec.com.mxPurpose: To propose a method for quantification of vitreous hemorrhages (VH) termed minimum image gain (MIG). Therefore, to obtain MIG measurements in patients with VH and to compare them to normal controls; to compare results between graders; and to obtain and compare MIG from two different ultrasound systems.Methods: Retrospective and cross-sectional, observational, and comparative study performed in two parts: Part 1) Retrospective comparison of MIG in VH vs controls by two experienced graders, with intra/inter-observer variability: MIG technique is described. MIG is performed retrospectively in two groups, VH patients and normal controls. Groups are compared with independent samples t-test. Intra- and interobserver variability between graders was obtained. Part 2) Cross-sectional analysis of variability from nonexperienced graders and with different ultrasound systems: MIG is performed in cross-sectional measurements of VH patients, by two unexperienced graders, and with two ultrasound systems. Interobserver variability and Bland–Altman plot with levels of agreement (LoA) were obtained.Results: Part 1: 50 patients with VH resulted in mean MIG: 52.8 dB; 34 controls resulted in mean MIG: 77.97 dB. Independent samples t-test resulted in a statistical significant difference. Intra- and inter-observer variability resulted in an almost perfect agreement between experienced graders. Part 2: 63 patients with VH, mean MIG: 56.19 dB. Inter-observer variability resulted in a very high agreement between unexperienced observers. LoA resulted in a statistical difference between the two ultrasound systems.Conclusion: MIG may provide an objective and reproducible way to quantify vitreous hemorrhage density and potentially any vitreous humor opacity. Agreement is high even with unexperienced graders. However, the two ultrasound systems analyzed may not be interchangeable.Keywords: diagnostic imaging, retina, ultrasonography, vitreous hemorrhage, vitreous humor

Published
2019

4. Long-term follow-up of patients with choroidal neovascularization due to angioid streaks

Author

Martinez-Serrano MG, Rodriguez-Reyes A, Guerrero-Naranjo JL, Salcedo-Villanueva G, Fromow-Guerra J, García-Aguirre G, Morales-Canton V, and Velez-Montoya R

Subjects
Angioid Streaks, Choroidal neovascularization, long term, antiangiogenic, bevacizumab, ranibizumab, outcome., Ophthalmology, RE1-994
Abstract

Maria Guadalupe Martinez-Serrano,1 Abelardo Rodriguez-Reyes,2 Jose Luis Guerrero-Naranjo,1,3 Guillermo Salcedo-Villanueva,1 Jans Fromow-Guerra,1,3 Gerardo García-Aguirre,1,3 Virgilio Morales-Canton,1 Raul Velez-Montoya1,3 1Retina Department, 2Pathology Department, Asociación para Evitar la Ceguera en Mexico, Hospital “Dr Luis Sanchez Bulnes” IAP, 3Macula Retina Consultants, Mexico City, Mexico Background: The following case series describes the long-term anatomical and functional outcome of a group of seven patients with choroidal neovascularization (CNV), secondary to angioid streaks (AS), who were treated with antiangiogenic drugs in a pro re nata (PRN) regimen. After the 4-year mark, visual acuity tends to return to pretreatment level. Treatment delays and lack of aware­ness and self-referral by the patients are believed to be the cause of the PRN regimen failure. Purpose: To assess the long-term outcomes (>4 years) of patients with CNV due to AS treated with a PRN regimen of antiangiogenic. Methods: This was a retrospective, case series, single-center study. We reviewed the electronic medical records from patients with CNV due to AS. From each record, we noted general demographic data and relevant medical history; clinical presentation, changes in best-corrected visual acuity (BCVA) over time, optical coherent tomography parameters, treatment and retreatment details, and systemic associations. Changes in BCVA and central macular thickness were assessed with a Wilcoxon two-sample test, with an alpha value of ≤0.05 for statistical significance. Results: The mean follow-up time was 53.8±26.8 months. BCVA at baseline was: 1.001±0.62 logMAR; at the end of follow-up: 0.996±0.56 logMAR (P=0.9). Central macular thickness at baseline was: 360.85±173.82 µm; at the end of follow-up: 323.85±100.34 µm (P=0.6). Mean number of intravitreal angiogenic drugs: 6±4.16 injections (range 4–15). Mean time between injections was 3.8±2.7 months (range 1.9–5.8 months). Conclusion: Despite initial anatomical and functional improvement, patients at the end of the follow-up had no visual improvement after a pro re nata regimen of antiangiogenic drugs. The amount of retreatments, number of recurrences, and time between intravitreal injections were similar to previous reports with shorter follow-up. Keywords: angioid streaks, choroidal neovascularization, long term, antiangiogenic, bevacizumab, ranibizumab, outcome

Published
2016

5. Combined Therapeutic Penetrating Keratoplasty and Pars Plana Vitrectomy for the Treatment of Infectious Keratitis Endophthalmitis: Mexican Endophthalmitis Study Group Protocol 4

Author

Velez-Montoya, Raul, Rivera-Cortes, Mariana A., Ledesma-Gil, Gerardo, Carranza-Casas, Mario, Martinez, Jaime D., Levine, Harry, Yanuzzi, Nicolas A., Amescua, Guillermo, Ahmed, Ishrat, Beatson, Bradley, Akpek, Esen, Arevalo, J. Fernando, Fromow-Guerra, Jans, Velez-Montoya, R., García-Aguirre, G., Salcedo-Villanueva, G., Fromow-Guerra, J., Guerrero-Naranjo, J.L., Morales-Canton, V., Dalma-Weiszhausz, J., Quiroz-Mercado, H., Jimenez-Sierra, J.M., Martinez-Castellanos, M.A., Soberon-Ventura, V., Cernichiaro, L., Rojas-Juarez, S., Ramirez-Estudillo, A., Hernández-Vázquez, A.Y., Ledesma-Gil, G., Graue-Weichers, F., Fulda-Graue, E., Ariza-Camacho, E., López-Bolaños, A., Rodríguez-Loaiza, J.L., Lozano-Rechy, D., Moreno-Paramo, D., Flores-Peredo, V., García-Franco, R., Ramirez-Neria, P., Mira-Lorenzo, X., Hernández-Da Mota, S., Bejar-Cornejo, F., and Rodriguez-Valdez, P.J.

Published
2023
Full Text
View/download PDF

7. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

Author

Siddiqi, Z. A., Nowak, R. J., Mozaffar, T., O'Brien, F., Yountz, M., Patti, F., Mazia, C. G., Wilken, M., Barroso, F., Saba, J., Rugiero, M., Bettini, M., Chaves, M., Vidal, G., Garcia, A. D., De Bleecker, J., Van den Abeele, G., de Koning, K., De Mey, K., Mercelis, R., Mahieu, D., Wagemaekers, L., Van Damme, P., Depreitere, A., Schotte, C., Smetcoren, C., Stevens, O., Van Daele, S., Vandenbussche, N., Vanhee, A., Verjans, S., Vynckier, J., D'Hont, A., Tilkin, P., de Siqueira Carvalho, A. A., Brockhausen, I. D., Feder, D., Ambrosio, D., Cesar, P., Melo, A. P., Ribeiro, R. M., Rocha, R., Rosa, B. B., Veiga, T., da Silva, L. A., Engel, M. S., Geraldo, J. G., da Penha Ananias Morita, M., Coelho, E. N., Paiva, G., Pozo, M., Prando, N., Torres, D. D. M., Butinhao, C. F., Duran, G., Fialho, T. A. S., da Silva, T. C. G., Goncalves, L. O. M., Pazetto, L. E., Volpe, L. R. C., Duca, L. S., Friedrich, M. A. G., Guerreiro, A., Mohr, H., Martins, M. P., da Cruz Pacheco, D., Ferreira, L., Macagnan, A. P., Pinto, G., de Cassia Santos, A., Oliveira, A. S. B., de Andrade, A. C. A., Annes, M., Silva, L. D., Lino, V. C., Pinto, W., Assis, N., Carrara, F., Miranda, C., Souza, I., Fernandes, P., Phan, C., Narayan, J., Blackmore, D., Mallon, A., Roderus, R., Watt, E., Vohanka, S., Bednarik, J., Chmelikova, M., Cierny, M., Toncrova, S., Junkerova, J., Kurkova, B., Reguliova, K., Zapletalova, O., Pitha, J., Novakova, I., Tyblova, M., Jurajdova, I., Wolfova, M., Andersen, H., Harbo, T., Vinge, L., Krogh, S., Mogensen, A., Vissing, J., Hojgaard, J., Witting, N., Autzen, A. M. O., Pedersen, J., Eralinna, J. -P., Laaksonen, M., Oksaranta, O., Harrison, T., Eriksson, J., Rozsa, C., Horvath, M., Lovas, G., Matolcsi, J., Szabo, G., Jakab, G., Szabadosne, B., Vecsei, L., Dezsi, L., Varga, E., Konyane, M., Antonini, G., Di Pasquale, A., Garibaldi, M., Morino, S., Troili, F., Fionda, L., Sacca, F., Filla, A., Costabile, T., Marano, E., Fasanaro, A., Marsili, A., Puorro, G., Mantegazza, R., Antozzi, C., Bonanno, S., Camera, G., Locatelli, A., Maggi, L., Pasanisi, M., Campanella, A., Evoli, A., Alboini, P. E., D'Amato, V., Iorio, R., Inghilleri, M., Frasca, V., Giacomelli, E., Gori, M., Lopergolo, D., Onesti, E., Gabriele, M., Uzawa, A., Kanai, T., Kawaguchi, N., Mori, M., Kaneko, Y., Kanzaki, A., Kobayashi, E., Murai, H., Masaki, K., Matsuse, D., Matsushita, T., Uehara, T., Shimpo, M., Jingu, M., Kikutake, K., Nakamura, Y., Sano, Y., Utsugisawa, K., Nagane, Y., Kamegamori, I., Tsuda, T., Fujii, Y., Futono, K., Ozawa, Y., Mizugami, A., Saito, Y., Samukawa, M., Suzuki, H., Morikawa, M., Kamakura, S., Miyawaki, E., Shiraishi, H., Miyazaki, T., Motomura, M., Mukaino, A., Yoshimura, S., Asada, S., Yoshida, S., Amamoto, S., Kobashikawa, T., Koga, M., Maeda, Y., Takada, K., Takada, M., Tsurumaru, M., Yamashita, Y., Suzuki, Y., Akiyama, T., Narikawa, K., Tano, O., Tsukita, K., Kurihara, R., Meguro, F., Fukuda, Y., Sato, M., Okumura, M., Funaka, S., Kawamura, T., Nakamori, M., Takahashi, M., Taichi, N., Hasuike, T., Higuchi, E., Kobayashi, H., Osakada, K., Imai, T., Tsuda, E., Shimohama, S., Hayashi, T., Hisahara, S., Kawamata, J., Murahara, T., Saitoh, M., Suzuki, S., Yamamoto, D., Ishiyama, Y., Ishiyama, N., Noshiro, M., Takeyama, R., Uwasa, K., Yasuda, I., Kim, B. -J., Lee, C. N., Koo, Y. S., Seok, H. Y., Kang, H. N., H. J., Ra, Kim, B. J., Cho, E. B., Choi, M. S., Lee, H. L., Min, J. -H., Seok, J., Lee, J. E., Koh, D. Y., Kwon, J. Y., Park, S. A., Choi, E. H., Hong, Y. -H., Ahn, S. -H., Koo, D. L., Lim, J. -S., Shin, C. W., Hwang, J. Y., Kim, M., Kim, S. M., Jeong, H. -N., Jung, J. W., Kim, Y. -H., Lee, H. S., Shin, H. Y., Hwang, E. B., Shin, M., van der Kooi, A., de Visser, M., Gibson, T., Casasnovas, C., Aguilo, M. A. A., Homedes-Pedret, C., Palacios, N. J., Porras, L. D., Santamaria, V. V., Lazaro, A., Tejedor, E. D., Salcedo, P. G., Fernandez-Fournier, M., Ruiz, P. L., de Rivera, F. J. R., Sastre, M., Carbonell, J. G., Sune, P., Figueras, M. S., Gili, G., Mazuela, G., Illa, I., Vicente, E. C., Diaz-Manera, J., Gutierrez, L. A. Q., Garcia, R. R., Vidal, N., Arribas-Ibar, E., Piehl, F., Hietala, A., Bjarbo, L., Sengun, I., Meherremova, A., Ozcelik, P., Balkan, B., Tuga, C., Ugur, M., Erdem-Ozdamar, S., Bekircan-Kurt, C. E., Acar, N. P., Yilmaz, E., Caliskan, Y., Orsel, G., Efendi, H., Aydinlik, S., Cavus, H., Kutlu, A., Becerikli, G., Semiz, C., Tun, O., Terzi, M., Dogan, B., Onar, M. K., Sen, S., Cavdar, T. K., Veske, A., Norwood, F., Dimitriou, A., Gollogly, J., Mahdi-Rogers, M., Seddigh, A., Sokratous, G., Maier, G., Sohail, F., Jacob, S., Sadalage, G., Torane, P., Brown, C., Shah, A., Sathasivam, S., Arndt, H., Davies, D., Watling, D., Amato, A., Cochrane, T., Salajegheh, M., Roe, K., Amato, K., Toska, S., Wolfe, G., Silvestri, N., Patrick, K., Zakalik, K., Katz, J., Miller, R., Engel, M., Forshew, D., Bravver, E., Brooks, B., Sanjak, M., Plevka, S., Burdette, M., Cunningham, S., Kramer, M., Nemeth, J., Schommer, C., Scott, T., Juel, V., Guptill, J., Hobson-Webb, L., Massey, J., Beck, K., Carnes, D., Loor, J., Anderson, A., Pascuzzi, R., Bodkin, C., Kincaid, J., Snook, R., Guingrich, S., Micheels, A., Chaudhry, V., Corse, A., Mosmiller, B., Kelley, A., Ho, D., Srinivasan, J., Vytopil, M., Jara, J., Ventura, N., Carter, C., Donahue, C., Herbert, C., Scala, S., Weiner, E., Alam, S., Mckinnon, J., Haar, L., Mckinnon, N., Alcon, K., Mckenna, K., Sattar, N., Daniels, K., Jeffery, D., Freimer, M., Hoyle, J. C., Kissel, J., Agriesti, J., Chelnick, S., Mezache, L., Pineda, C., Muharrem, F., Karam, C., Khoury, J., Marburger, T., Kaur, H., Dimitrova, D., Gilchrist, J., Agrawal, B., Elsayed, M., Kohlrus, S., Ardoin, A., Darnell, T., Golden, L., Lokaitis, B., Seelbach, J., Muppidi, S., Goyal, N., Sakamuri, S., Y. T., So, Paulose, S., Pol, S., Welsh, L., Bhavaraju-Sanka, R., Gonzalez, A. T., Dishman, L., Jones, F., Gonzalez, A., Padilla, P., Saklad, A., Silva, M., Nations, S., Trivedi, J., Hopkins, S., Kazamel, M., Alsharabati, M., Lu, L., Nozaki, K., Mumfrey-Thomas, S., Woodall, A., Cash, T., Roy, G., Mathew, V., Maqsood, F., Minton, B., Jones, H. J., Rosenfeld, J., Garcia, R., Echevarria, L., Garcia, S., Pulley, M., Aranke, S., Berger, A. R., Shah, J., Shabbir, Y., Smith, L., Varghese, M., Gutmann, L., Jerath, N., Nance, C., Swenson, A., Olalde, H., Kressin, N., Sieren, J., Barohn, R., Dimachkie, M., Glenn, M., Mcvey, A., Pasnoor, M., Statland, J., Wang, Y., Liu, T., Emmons, K., Jenci, N., Locheke, J., Fondaw, A., Johns, K., Rico, G., Walsh, M., Herbelin, L., Hafer-Macko, C., Kwan, J., Zilliox, L., Callison, K., Young, V., Disanzo, B., Naunton, K., Benatar, M., Bilsker, M., Sharma, K., Cooley, A., Reyes, E., Michon, S. -C., Sheldon, D., Steele, J., Howard, J., Traub, R., Chopra, M., Vu, T., Katzin, L., Mcclain, T., Harvey, B., Hart, A., Huynh, K., Beydoun, S., Chilingaryan, A., Doan, V., Droker, B., Gong, H., Karimi, S., Lin, F., Polaka, K., Tran, A., Akhter, S., Malekniazi, A., Tandan, R., Hehir, M., Waheed, W., Lucy, S., Weiss, M., Distad, J., Strom, S., Downing, S., Kim, B., Bertorini, T., Arnold, T., Henderson, K., Pillai, R., Liu, Y., Wheeler, L., Hewlett, J., Vanderhook, M., Dicapua, D., Keung, B., Kumar, A., Patwa, H., Robeson, K., Yang, I., Nye, J., Vu, H., Neurology, ANS - Neuroinfection & -inflammation, and EURO-NMD

Subjects
medicine.medical_specialty, Physiology, Population, Subgroup analysis, Antibodies, Monoclonal, Humanized, Placebo, Cellular and Molecular Neuroscience, rituximab, Refractory, immune system diseases, Physiology (medical), Internal medicine, Activities of Daily Living, medicine, Humans, education, education.field_of_study, myasthenia gravis, acetylcholine receptor, business.industry, Eculizumab, medicine.disease, Confidence interval, Myasthenia gravis, refractory, Rituximab, eculizumab, Neurology (clinical), business, medicine.drug
Abstract

Introduction/Aims: Individuals with refractory generalized myasthenia gravis (gMG) who have a history of rituximab use and experience persistent symptoms represent a population with unmet treatment needs. The aim of this analysis was to evaluate the efficacy and safety of eculizumab in patients with refractory anti-acetylcholine receptor antibody-positive (AChR+) gMG previously treated with rituximab. Methods: This post hoc subgroup analysis of the phase 3 REGAIN study (NCT01997229) and its open-label extension (OLE; NCT02301624) compared baseline characteristics, safety, and response to eculizumab in participants who had previously received rituximab with those who had not. Rituximab use was not permitted within the 6 months before screening or during REGAIN/OLE. Results: Of 125 REGAIN participants, 14 had received rituximab previously (7 received placebo and 7 received eculizumab). In the previous-rituximab group, 57% had used at least four other immunosuppressants compared with 16% in the no-previous-rituximab group. Myasthenia Gravis Activities of Daily Living total scores from eculizumab baseline to week 130 of eculizumab treatment improved in both the previous-rituximab and no-previous-rituximab groups (least-squares mean −4.4, standard error of the mean [SEM] 1.0 [n = 9] and least-squares mean −4.6, SEM 0.3 [n = 67], respectively; difference = 0.2, 95% confidence interval −1.88 to 2.22). In addition, in both groups, most patients who were treated with eculizumab for 130 weeks achieved a Myasthenia Gravis Foundation of America post-intervention status of minimal manifestations (66.7% and 65.0%, respectively). The eculizumab safety profile was similar between groups and consistent with its established profile. Discussion: Eculizumab is an effective therapy for patients with refractory AChR+ gMG, irrespective of whether they had received rituximab treatment previously.

Published
2021

10. Lesión linfoproliferativa del saco lagrimal: caso clínico

Author

Coloma-González, I., Ruíz-García, L., Ceriotto, A., Corredor-Casas, S., and Salcedo-Casillas, G.

Abstract

Se presenta el caso de una mujer de 51 años con tumoración firme a nivel del canto interno del ojo derecho de 5 años de evolución. La biopsia excisional mediante dacriocistectomía estableció el diagnóstico de lesión linfoproliferativa de bajo grado (hiperplasia linfoide reactiva).

Published
2015
Full Text
View/download PDF

11. Metástasis orbitaria pulsátil como signo de presentación de carcinoma renal de células claras metastásico

Author

Coloma-González, I., Ceriotto, A., Amezquita-García, E., Flores-Preciado, J., and Salcedo-Casillas, G.

Abstract

Se presenta el caso de un varón de 56 años con tumoración pulsátil en región temporal de la órbita izquierda como signo de presentación de un carcinoma metastásico de riñón, así como una revisión de todos los casos diagnosticados de metástasis orbitarias en nuestro hospital entre 1957 y 2012.

Published
2014
Full Text
View/download PDF

12. Endotheliitis, Shunts, and Ventilation–Perfusion Mismatch in Coronavirus Disease 2019: A Literature Review of Disease Mechanisms

Author

González-Ruiz, Francisco J., Lazcano-Díaz, Emmanuel A., Baeza Herrera, Luis A., Villalobos-Pedroza, Montserrat, Toledo Alemán, Enma L., Zuñiga-Salcedo, Miriam G., Cruz-Rodríguez, Camelia, López-Polanco, Alexandra, Torres-Pulido, Abraham, Sierra-González de Cossio, Alejandro, Cota Apodaca, Luis A., and Manzur-Sandoval, Daniel

Abstract

The severe acute respiratory syndrome coronavirus 2 pandemic has continued to impact global health. However, while immunity acquired by vaccines has been developed, 40% of the world's population has still not been vaccinated. Economic problems associated with acquiring novel therapies, misinformation, and differences in treatment protocols have generated catastrophic results, especially in low-resource countries. Understanding the pathophysiological aspects of coronavirus disease and the therapeutic strategies that have been validated to date is essential for successful medical care. In this review, I summarize the historical aspects of the virus, molecules involved in infecting the host, and consequences of viral interactions with and in tissues.

Published
2022
Full Text
View/download PDF

13. Enfermedad de Mikulicz. A propósito de un caso

Author

Coloma-González, I., Ruíz-García, L., Flores-Preciado, J., Encampira-Luna, E.O., Ceriotto, A., and Salcedo-Casillas, G.

Abstract

Se presenta el caso de un paciente de 48 años con afectación bilateral de las glándulas lacrimales y salivales que fue diagnosticado de enfermedad de Mikulicz mediante biopsia incisional de las glándulas lacrimales afectadas, presentando resolución completa del cuadro tras tratamiento corticoideo.

Published
2014
Full Text
View/download PDF

14. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia.

Author

Manber, Rachel, Edinger, Jack D, Gress, Jenna L, San Pedro-Salcedo, Melanie G, Kuo, Tracy F, and Kalista, Tasha

Abstract

Insomnia impacts the course of major depressive disorder (MDD), hinders response to treatment, and increases risk for depressive relapse. This study is an initial evaluation of adding cognitive behavioral therapy for insomnia (CBTI) to the antidepressant medication escitalopram (EsCIT) in individuals with both disorders.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results